Vilazodone pharmaceutical composition, its preparation method and application
A vilazodone pharmaceutical composition with controlled particle sizes and additives addresses frequent dosing and swallowing difficulties, achieving sustained release and improved patient compliance.
Patent Information
- Application Number
- JP2023538986
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-12-23
- Filing Date
- 2021-12-20
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2041-12-20
AI Technical Summary
Current vilazodone hydrochloride formulations face issues with frequent dosing, difficulty in swallowing, and unpleasant odor, affecting patient compliance, and there is a need for a pharmaceutical composition that provides sustained release and reduces dosing frequency.
A vilazodone pharmaceutical composition with vilazodone solid particles having specific particle sizes (Dv(10) ≤ 20 microns, Dv(50) ≤ 50 microns, and Dv(90) ≤ 100 microns, combined with carriers and additives like water, castor oil, and polymers, to achieve sustained release and improved patient compliance.
The composition offers improved long-term sustained release, reduced dosing frequency, and enhanced patient compliance, overcoming the drawbacks of conventional vilazodone hydrochloride tablets.
Smart Images

Figure 0007579028000018 
Figure 0007579028000019 
Figure 0007579028000020
Abstract
Description
Detailed Description of the Invention
[0001] This application claims priority to a prior application bearing application number 202011536858.1 and entitled "Vilazodone pharmaceutical composition, its preparation method and application," filed with the State Intellectual Property Office of the People's Republic of China on December 23, 2020, which is incorporated herein by reference in its entirety. [Technical field] The present invention relates to a pharmaceutical composition of vilazodone, its preparation method and application, which belongs to the field of pharmaceutical formulations. [Background technology] Depression is a common mental health disorder whose signs and symptoms include low mood, loss of interest in usual activities, noticeable changes in weight or appetite, insomnia or hypersomnia (lethargy), restlessness / pacing (psychomotor agitation), increased fatigue, feelings of guilt or inferiority, slowed thinking and inability to concentrate, and in severe cases, thoughts of self-harm and suicidal tendencies. The illness severely affects people's ability to work, sleep, learn, eat, and enjoy pleasurable activities.
[0002] Depression is thought to be caused by a decrease in the content of monoamine neurotransmitters such as central norepinephrine (NE), 5-hydroxytryptamine (5-HT), and dopamine (DA), as well as a decrease in their receptor function. Electrical shock therapy was used as the first treatment for depression, but the therapeutic effect was lost after repeated use. Currently, there are three main types of drugs used to treat depression. One is tricyclic antidepressants (TCAs), which can increase the concentrations of NE and 5-HT in the brain and have become the standard drug for treating depression. However, these drugs have a slow onset of effect and are accompanied by serious adverse reactions such as cardiac toxicity. The other type of antidepressant is monoamine oxidase inhibitors (MAOIs), which can delay the decomposition of NE and 5-HT in the brain and extend the duration of action of these neurotransmitters. In the 1980s, a new class of antidepressants, selective serotonin reuptake inhibitors (SSRIs), was developed, which inhibit the reuptake of 5-HT by the presynaptic membrane, increase the concentration of 5-HT in the synaptic cleft, and improve the excitability of the postsynaptic 5-HT1A receptors, resulting in antidepressant effects, while not affecting other neurotransmitter receptors, making them relatively safe. However, SSRIs are less effective than TCAs in treating severe depression, and because SSRIs stimulate various subtypes of 5-HT receptors nonselectively, there are some associated side effects. Researchers have found that buspirone inhibits 5-HT 1A They found that it has high affinity for the 5-HT receptor, which is a selective 1A This has facilitated the development of receptor agonist antidepressants.
[0003] Vilazodone hydrochloride, its English name is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-y1)butyl]-1-piperazinyl] hydrochloride(1:l), and its molecular formula is C 26 H 27The compound has a molecular weight of 477.99 and a chemical structure as follows:
[0004] [ka]
[0005] The U.S. Food and Drug Administration (FDA) approved vilazodone hydrochloride (brand name Viibryd) in plain tablets for the treatment of major depressive disorder in adults on January 21, 2011. Viibryd is manufactured by PGxHealth, New Haven, Conn. Vilazodone hydrochloride is a 5-hydroxytryptamine 1A (5-HT 1A It belongs to the dual-activity group of partial agonists and selective 5-hydroxytryptamine (5-HT) reuptake inhibitors (SSRIs), and is also the first new antidepressant of the indolealkylamine class.
[0006] Currently, the dosage forms of vilazodone hydrochloride available in overseas markets are 10 mg, 20 mg, and 40 mg. However, such low-dose tablets have the disadvantages of frequent dosing, difficulty in swallowing, and the unpleasant odor of the drug that affects patient compliance. Therefore, finding a pharmaceutical composition of vilazodone that can achieve long-term sustained release, reduce dosing frequency, and improve patient compliance is a technical problem that is urgently needed to be solved. Summary of the Invention In order to improve the above technical problems, the present invention provides a vilazodone pharmaceutical composition comprising vilazodone solid particles, the particle size of the vilazodone solid particles being Dv(10) less than or equal to 20 microns, Dv(50) less than or equal to 50 microns, and Dv(90) less than or equal to 100 microns.
[0007] According to an embodiment of the present invention, the solid particles of vilazodone may be selected from solid particles of vilazodone, a pharma- ceutically acceptable salt of vilazodone (eg, the hydrochloride salt) or a solvate thereof.
[0008] According to an embodiment of the present invention, the particle size of the vilazodone solid particles may be Dv(10) of 10 microns or less, or 8 microns or less, for example, 0.1 to 8 microns, such as 0.1 microns, 0.2 microns, 0.5 microns, 1 micron, 2 microns, 3 microns, 4 microns, 5 microns, 6 microns, 7 microns or 8 microns, examples of which may be 7.187 microns, 147.16 nanometers, 4.813 microns, 5.522 microns, 0.808 microns, 187.63 nanometers, 0.873 microns, 4.517 microns, 6.708 microns, 7.483 microns, 4.737 microns, 4.759 microns, 2.105 microns, 8.4 microns.
[0009] According to an embodiment of the present invention, the particle size of the vilazodone solid particles may be Dv(50) of 40 microns or less, or 30 microns or less, for example, 0.1 to 30 microns, for example, 0.1 microns, 0.2 microns, 0.5 microns, 1 micron, 2 microns, 3 microns, 4 microns, 5 microns, 6 microns, 7 microns, 8 microns, 9 microns, 10 microns, 11 microns, 12 microns, 13 microns, 14 microns, 15 microns, 16 microns, 17 microns, 18 microns, 19 microns, 20 microns, 21 microns, 22 microns, 23 microns, 24 microns, 25 microns, 26 microns, 27 microns, 28 microns, 29 microns, 30 microns, 31 microns, 32 microns, 33 microns, 34 microns, 35 microns, 36 microns, 37 microns, 38 microns, 39 microns, 40 microns, 41 microns, 42 microns, 43 microns, 44 microns, 45 microns, 46 microns, 47 microns, 48 microns, 49 microns, 50 microns, 51 microns, 52 microns, 53 microns, 54 microns, 55 microns, 56 microns, 57 microns, 58 microns, 59 microns, 60 microns, 61 microns, 62 microns, 63 microns, 64 microns, 65 microns, 66 microns, 67 microns, 68 microns, 69 microns, 70 microns, 71 microns, 72 microns, 73 The diameter may be 17.245 microns, 322.47 nanometers, 25.913 microns, 13.825 microns, 1.210 microns, 296.41 nanometers, 1.550 microns, 17.141 microns, 17.84 microns, 9.745 microns, 20.6 microns, or 30 microns.
[0010] According to an embodiment of the present invention, the particle size of the vilazodone solid particles may be Dv(90) of 80 microns or less, or 50 microns or less, for example, 0.1 to 50 microns, for example, 0.1 microns, 0.2 microns, 0.5 microns, 1 micron, 2 microns, 3 microns, 4 microns, 5 microns, 6 microns, 7 microns, 8 microns, 9 microns, 10 microns, 11 microns, 12 microns, 13 microns, 14 microns, 15 microns, 16 microns, 17 microns, 18 microns, 19 microns, 20 microns, 21 microns, 22 microns, 23 microns, 24 microns, 25 microns, 26 microns, 27 microns, 28 microns, 29 microns, 30 microns, 31 microns, 32 microns, 33 microns, 34 microns, 35 microns, 36 microns, 37 microns, 38 microns, 39 microns, 40 microns, 41 microns, 42 microns, 43 microns, 44 microns, 45 microns, 46 microns, 47 microns, 48 microns, 49 microns, 50 microns, 51 microns, 52 microns, 53 microns, 54 microns, 55 microns, 56 microns, 57 microns, 58 microns, 59 microns, 60 microns, 61 microns, 62 microns, 63 microns, 64 microns, 65 microns, 66 microns, 67 microns, 68 microns, 69 microns, 70 microns, 71 microns, 72 microns, 73 57.063 microns, 39.93 microns, 43.9 microns, 44.18 nanometers, 45.06 microns, 46.06 microns, 47.18 nanometers, 48.06 microns, 49.18 nanometers, 57.063 microns, 46.06 microns, 47.18 nanometers, 48.06 microns, 49.18 nanometers, 40.06 microns, 41.06 microns, 42.18 nanometers, 43.06 microns, 44.18 nanometers, 45.06 microns, 46.06 microns, 47.18 nanometers, 48.06 microns, 49.18 nanometers, 57.063 microns, 46.06 microns, 47.18 nanometers, 48 ...
[0011] According to an embodiment of the present invention, the vilazodone pharmaceutical composition may further include a carrier. The carrier may be a non-oil carrier or an oil carrier. The non-oil carrier includes, but is not limited to, water. The water may be a commercially available water for injection, preferably sterile water for injection. The oil carrier includes, but is not limited to, one or more of castor oil, triglyceride, cottonseed oil, sesame oil, etc.
[0012] According to an embodiment of the present invention, the vilazodone pharmaceutical composition may further comprise one or more selected from suspending agents, wetting agents, osmotic pressure adjusting agents, solvents, stabilizers, buffers, pH adjusting agents, surfactants, polymers, electrolytes and non-electrolytes, wherein the polymers may be cross-linked polymers and / or non-cross-linked polymers.
[0013] According to an embodiment of the present invention, the suspending agent includes one or more of, but is not limited to, sodium carboxymethylcellulose, polyethylene glycol, and povidone.
[0014] According to an embodiment of the present invention, the wetting agent includes, but is not limited to, one or more of poloxamer, povidone, docusate sodium, sodium deoxycholate and Tween. The Tween may be a commonly available Tween reagent, such as one or more selected from Tween 20 and Tween 80.
[0015] According to an embodiment of the present invention, the osmolality adjusting agent includes one or more of, but is not limited to, sodium chloride, mannitol, and sucrose.
[0016] According to an embodiment of the present invention, the solvent includes, but is not limited to, water for injection.
[0017] According to an embodiment of the present invention, the stabilizer includes, but is not limited to, one or more of antioxidants, metal ion chelators, polyethylene oxide (PEO), polyethylene oxide derivatives, polysorbates, sodium deoxycholate, sodium docusate, poloxamers, polyethoxylated vegetable oils, polyethoxylated castor oil, sorbitan palmitate, lecithin, polyvinyl alcohol, human serum albumin, polyvinylpyrrolidone, povidone, polyethylene glycol, sodium chloride, calcium chloride, dextrose, glycerol, mannitol, and cross-linked polymers. The antioxidants include, but are not limited to, one or more of citric acid, vitamin C, and vitamin E. The metal ion chelators include, but are not limited to, ethylenediaminetetraacetic acid (EDTA). The poloxamers include, but are not limited to, one or more of poloxamer 188, poloxamer 124, and poloxamer 407. The polysorbates include, but are not limited to, one or more of polysorbate 80 and polysorbate 20. The povidones include, but are not limited to, one or more of povidone K12, povidone K17, PLASDONE™ C-12 povidone, PLASDONE™ C-17 povidone, and PLASDONE™ C-30 povidone. The polyethylene glycols include, but are not limited to, polyethylene glycol 3350. The cross-linked polymers include, but are not limited to, sodium carboxymethylcellulose.
[0018] According to an embodiment of the present invention, the buffering agent includes, but is not limited to, phosphoric acid, phosphates, citric acid, sodium citrate, tris(hydroxymethyl)aminomethane (Tris), sodium hydroxide, hydrochloric acid (HCl), or mixtures thereof.
[0019] According to an embodiment of the present invention, the pH adjuster includes, but is not limited to, phosphoric acid, phosphates, citric acid, sodium citric acid, hydrochloric acid, and sodium hydroxide.
[0020] According to an embodiment of the invention, the phosphate salt includes, but is not limited to, one or more of sodium dihydrogen phosphate, disodium hydrogen phosphate, anhydrous or hydrated sodium dihydrogen phosphate, anhydrous or hydrated disodium hydrogen phosphate, such as one or more of disodium hydrogen phosphate monohydrate (NaHPO·HO), disodium hydrogen phosphate dihydrate (NaHPO·2HO), anhydrous disodium hydrogen phosphate (anhydrous NaHPO), sodium dihydrogen phosphate monohydrate (NaHPO·HO), sodium dihydrogen phosphate dihydrate (NaHPO·2HO) and anhydrous sodium dihydrogen phosphate (anhydrous NaHPO).
[0021] According to an embodiment of the present invention, the co-solvents include one or more of, but are not limited to, ethanol and propylene glycol.
[0022] In the vilazodone pharmaceutical composition, the weight fraction of the vilazodone solid particles may be 1.00% to 50.00%, and may be 2.00% to 45.00%, for example, 2.00%, 3.00%, 4.00%, 5.00%, 6.00%, 7.00%, 8.00%, 9.00%, 10.00%, 11.00%, 12.00%, 13.00%, 14.00%, 15.00%, 16.00%, 17.00%, 18.00%, 19.00%, 20.00%, 21.00%, 22.00%, 23.00%, 24.00%, 25.00%, 26.00%, 27.00%, 28.00%, 29.00%, 30.00%, 31.00%, 32.00%, 33.00%, 34.00%, 35.00%, 36.00%, 37.00%, 38.00%, 39.00%, 40.00%, 41.00%, 42.00%, 43.00%, 44.00%, 45.00%, 46.00%, 47.00%, 48.00%, 49.00%, 50.00%, 51.00%, 52.00%, 53.00%, 54.00%, 55.00%, 56.00%, 57.00%, 58.00%, 59.00%, 60.00%, 61.00%, 62.00%, 63.00%, 64.00%, 65.00%, 66.00%, 67.00 The weight fraction may be 0.00%, 18.00%, 19.00%, 20.00%, 21.00%, 22.00%, 23.00%, 24.00%, 25.00%, 30.00%, 35.00%, 40.00% or 45.00%, illustratively 5.00% or 30.00%; said weight fraction being the percentage of the weight of the vilazodone solid particles in the total weight of the vilazodone pharmaceutical composition.
[0023] In the vilazodone pharmaceutical composition, the weight fraction of the wetting agent may be 0-5.00%, such as 1.00%, 2.00%, 3.00%, 4.00%, 5.00%, for example, 1.00%; the weight fraction is the percentage of the weight of the surfactant in the total weight of the vilazodone pharmaceutical composition.
[0024] In the vilazodone pharmaceutical composition, the weight fraction of the osmotic adjuster may be 0-5.00%, for example, 0, 1.00%, 2.00%, 3.00%, 4.00%, 5.00%, for example, 2.15%; the weight fraction is the percentage of the weight of the osmotic adjuster in the total weight of the vilazodone pharmaceutical composition.
[0025] In the vilazodone pharmaceutical composition, the weight fraction of the buffering agent may be 0-1.00%, for example, 0, 0.10%, 0.20%, 0.30%, 0.40%, 0.50%, 0.60%, 0.70%, 0.80%, 0.90%, 1.00%; the weight fraction is the percentage of the weight of the buffering agent in the total weight of the vilazodone pharmaceutical composition.
[0026] In the vilazodone pharmaceutical composition, the weight fraction of the stabilizer may be 0-1.00%, for example, 0, 0.10%, 0.20%, 0.30%, 0.40%, 0.50%, 0.60%, 0.70%, 0.80%, 0.90%, 1.00%, for example, 0.60%; the weight fraction is the percentage of the weight of the stabilizer in the total weight of the vilazodone pharmaceutical composition.
[0027] In the vilazodone pharmaceutical composition, the amount of the pH adjuster used may be such that the pH of the composition solution is adjusted to 6.5 to 8.0, for example 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 or 8.0, for example 7.4.
[0028] The vilazodone pharmaceutical composition may contain the following components by weight percentage: 1.00%-50.00% vilazodone solid particles, 0-5.00% wetting agent, 0-5.00% stabilizer, 0-5.00% osmotic pressure adjusting agent, 0-1.00% buffer salt and solvent.
[0029] Alternatively, in the vilazodone pharmaceutical composition, the weight / volume (g / mL) percentage of the vilazodone solid particles may be 1.00% to 50.00%, and may be 2.00% to 45.00%, for example, 2.00%, 3.00%, 4.00%, 5.00%, 6.00%, 7.00%, 8.00%, 9.00%, 10.00%, 11.00%, 12.00%, 13.00%, 14.00%, 15.00%, 16.00%, 17.00%, 18.00%, 19.00%, 20.00%, 21.00%, 22.00%, 23.00%, 24.00%, 25.00%, 26.00%, 27.00%, 28.00%, 29.00%, 30.00%, 31.00%, 32.00%, 33.00%, 34.00%, 35.00%, 36.00%, 37.00%, 38.00%, 39.00%, 40.00%, 41.00%, 42.00%, 43.00%, 44.00%, 45.00%, 46.00%, 47.00%, 48.00%, 49.00%, 50.00%, 51.00%, 52.00%, 53.00%, 54.00%, 55.00%, 56.00%, 57.00%, 58.00%, 59.00%, 60.00%, 61.00%, 62.00%, 63.00%, 64.00%, 65.00%, 66 0%, 13.00%, 14.00%, 15.00%, 16.00%, 17.00%, 18.00%, 19.00%, 20.00%, 21.00%, 22.00%, 23.00%, 24.00%, 25.00%, 30.00%, 35.00%, 40.00% or 45.00%, and illustrative examples thereof may be 5.00% or 30.00%.
[0030] In the vilazodone pharmaceutical composition, the weight / volume (g / mL) percentage of the wetting agent may be 0-5.00%, such as 1.00%, 2.00%, 3.00%, 4.00%, 5.00%, e.g., 1.00%; wherein the percentage is the mass / volume percentage (g / mL) of the weight of the component relative to the volume of the vilazodone pharmaceutical composition.
[0031] In the vilazodone pharmaceutical composition, the weight / volume (g / mL) percentage of the osmotic agent may be 0-5.00%, such as 0, 1.00%, 2.00%, 3.00%, 4.00%, 5.00%, e.g., 2.15%; wherein the percentage is the mass / volume percentage (g / mL) of the weight of the component relative to the volume of the vilazodone pharmaceutical composition.
[0032] In the vilazodone pharmaceutical composition, the weight / volume (g / mL) percentage of the buffering agent may be 0-1.00%, for example, 0, 0.10%, 0.20%, 0.30%, 0.40%, 0.50%, 0.60%, 0.70%, 0.80%, 0.90%, 1.00%; wherein the percentage is the mass / volume percentage (g / mL) of the weight of the component relative to the volume of the vilazodone pharmaceutical composition.
[0033] In the vilazodone pharmaceutical composition, the weight / volume (g / mL) percentage of the stabilizer may be 0-1.00%, for example, 0, 0.10%, 0.20%, 0.30%, 0.40%, 0.50%, 0.60%, 0.70%, 0.80%, 0.90%, 1.00%, for example, 0.60%; wherein the percentage is the mass / volume percentage (g / mL) of the weight of the component relative to the volume of the vilazodone pharmaceutical composition.
[0034] In the vilazodone pharmaceutical composition, the amount of the pH adjuster used may be such that the pH of the composition solution is adjusted to 6.5 to 8.0, for example 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 or 8.0, for example 7.4.
[0035] The vilazodone pharmaceutical composition may contain the following components in weight / volume (g / mL) percentages: 1.00%-50.00% vilazodone solid particles, 0-5.00% humectant, 0-5.00% stabilizer, 0-5.00% osmolality adjuster, 0-1.00% buffer salts and solvents; wherein the percentages refer to the mass / volume percentage (g / mL) of the weight of each component relative to the volume of the vilazodone pharmaceutical composition.
[0036] According to an embodiment of the present invention, the vilazodone pharmaceutical composition may be selected from any one of the following formulations: Formulation A: 30% vilazodone hydrochloride, 1% Tween 20, 2.15% mannitol, 0.08% anhydrous sodium dihydrogen phosphate, 0.4% anhydrous disodium hydrogen phosphate, and the remainder is preferably water, the percentages being the weight percentages of each component in the total weight of the vilazodone pharmaceutical composition; Formulation B: 5% vilazodone hydrochloride, 1% Tween 20, 0.3% PVPK12, 0.3% sodium deoxycholate, and the remainder is preferably water, the percentages being the weight percentages of each component relative to the total weight of the vilazodone pharmaceutical composition; Formulation c: 20% vilazodone hydrochloride, 1% Tween 20, 0.3% PVPk12, 0.3% sodium deoxycholate, 0.45% disodium hydrogen phosphate, 0.09% sodium dihydrogen phosphate, 2.5% mannitol, 0.18% sodium carboxymethylcellulose, and the remainder is preferably water, the percentages being the weight percentages of each component relative to the total weight of the vilazodone pharmaceutical composition; Formulation d: 36.3% vilazodone hydrochloride, 0.91% Tween 20, 0.34% disodium hydrogen phosphate, 0.07% sodium dihydrogen phosphate, 2.0% mannitol, 0.21% sodium carboxymethylcellulose, and the remainder is preferably water, the percentages being the weight percentages of each component relative to the total weight of the vilazodone pharmaceutical composition; Formulation e: 30% vilazodone hydrochloride, 1% Tween 20, 0.38% disodium hydrogen phosphate, 0.08% sodium dihydrogen phosphate, 2.20% mannitol, 0.23% sodium carboxymethylcellulose, and the remainder is preferably water, the percentages being the weight percentages of each component in the total weight of the vilazodone pharmaceutical composition; Formulation f: 30%-40% vilazodone hydrochloride, 1% Tween 20, 0%-0.3% PVP K12, 0.33%-0.39% disodium hydrogen phosphate, 0.07%-0.08% sodium dihydrogen phosphate, 1.6%-2.2% mannitol, 0%-1.0% sodium carboxymethylcellulose, and the remainder is preferably water, the percentages being the weight of each component relative to the total weight of the vilazodone pharmaceutical composition.
[0037] The formulation is preferably 30% vilazodone hydrochloride, 1% Tween 20, 2.15% mannitol, 0.08% anhydrous sodium dihydrogen phosphate, 0.4% anhydrous disodium hydrogen phosphate, and the remainder is water, and the percentages are mass / volume percentages (g / mL) of the weight of each component relative to the volume of the vilazodone pharmaceutical composition. The formulation bv is preferably 5% vilazodone hydrochloride, 1% Tween 20, 0.3% PVPK12, 0.3% sodium deoxycholate, and the remainder is water, and the percentages are mass / volume percentages (g / mL) of the weight of each component relative to the volume of the vilazodone pharmaceutical composition; Formulation cv: 20% vilazodone hydrochloride, 1% Tween 20, 0.3% PVPk12, 0.3% sodium deoxycholate, 0.45% disodium hydrogen phosphate, 0.09% sodium dihydrogen phosphate, 2.5% mannitol, 0.18% sodium carboxymethylcellulose, and the remainder is preferably water, and the percentages are mass / volume percentages (g / mL) of the weight of each component relative to the volume of the vilazodone pharmaceutical composition, The formulation dv is preferably 36.3% vilazodone hydrochloride, 0.91% Tween 20, 0.34% disodium hydrogen phosphate, 0.07% sodium dihydrogen phosphate, 2.0% mannitol, 0.21% sodium carboxymethylcellulose, and the remainder is water, and the percentages are mass / volume percentages (g / mL) of the weight of each component relative to the volume of the vilazodone pharmaceutical composition, Formulation ev: 30% vilazodone hydrochloride, 1% Tween 20, 0.38% disodium hydrogen phosphate, 0.08% sodium dihydrogen phosphate, 2.20% mannitol, 0.23% sodium carboxymethylcellulose, and the remainder is preferably water, the percentages being the mass / volume percentage (g / mL) of the weight of each component relative to the volume of the vilazodone pharmaceutical composition; Formulation fv: 30%-40% vilazodone hydrochloride, 1% Tween 20, 0%-0.3% PVP K12, 0.33%-0.39% disodium hydrogen phosphate, 0.07%-0.08% sodium dihydrogen phosphate, 1.6%-2.2% mannitol, 0%-1.0% sodium carboxymethylcellulose, and the remainder is preferably water, the percentages being the mass / volume percentage (g / mL) of the weight of each component relative to the volume of the vilazodone pharmaceutical composition.
[0038] According to an embodiment of the present invention, the sedimentation volume ratio (H / H0) of the vilazodone pharmaceutical composition is 0.8 or more, such as 0.8-1.0, for example 0.81-0.99, but preferably greater than 0.8.
[0039] The present invention further provides a method for preparing said vilazodone pharmaceutical composition, comprising the steps of: Step 1: Vilazodone solid particles are mixed with other ingredients in the formulation to obtain a premix; Step 2: The premix obtained in step 1 is polished with zirconium beads to obtain the vilazodone pharmaceutical composition.
[0040] In step 1, the mixing is preferably performed by stirring.
[0041] In step 2, the particle size of the zirconium beads may be 0.01 mm to 2 mm, for example 0.1 mm, 0.3 mm, 0.6 mm or 1 mm, for example 0.3 mm.
[0042] In step 2, the volume ratio of the zirconium beads to the premix is preferably 1-5, such as 1, 1.5, 2 or 3, for example 1.5.
[0043] In step 2, the polishing time may be from 1 minute to 24 hours, or may be from 5 minutes to 20 hours, for example, from 5 to 15 hours, for example, 10 hours.
[0044] According to an embodiment of the present invention, the zirconium beads are conventional commercially available zirconia beads.
[0045] The present invention further provides a vilazodone pharmaceutical formulation comprising said vilazodone pharmaceutical composition.
[0046] The present invention further provides the application of said vilazodone pharmaceutical composition in the manufacture of a medicament, such as in the manufacture of a vilazodone pharmaceutical formulation.
[0047] According to an embodiment of the invention, the medicament is 5-hydroxytryptamine 1A (5-HT 1A ) partial agonist and / or selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI); more preferably, the medicament is used for the prevention and / or treatment of depression, such as major depression in adults.
[0048] The vilazodone pharmaceutical formulation includes, but is not limited to, one or more of tablets, granules, capsules, micropellets, oral liquids, and injections, etc. Preferably, the tablets include, but are not limited to, one or more of sustained release tablets, osmotic pump tablets, and oral disintegrating tablets. Preferably, the injections can be liquid injections, injection powders, or injection tablets, for example, the liquid injections can be suspensions, such as water suspensions or powders for suspension, for example, the powders for suspension are freeze-dried powders.
[0049] According to an embodiment of the present invention, the injection may be a long-acting injection, which may be a water suspension or a powder for suspension, and is dispersed into a suspension with a specific diluent immediately before use.
[0050] According to an embodiment of the present invention, the concentration of vilazodone in the long-acting injectable is 50 mg / ml or more.
[0051] The present invention further provides a vilazodone pharmaceutical formulation comprising the above-described vilazodone pharmaceutical composition.
[0052] According to an embodiment of the present invention, the vilazodone pharmaceutical formulation has the dosage form selection and / or vilazodone concentration as described above.
[0053] The present invention relates to the vilazodone pharmaceutical composition, the medicament and / or the vilazodone pharmaceutical formulation, 1A ) partial agonists and / or selective 5-hydroxytryptamine (5-HT) reuptake inhibitors (SSRIs).
[0054] The present invention further provides the application of said vilazodone pharmaceutical composition, medicament and / or vilazodone pharmaceutical formulation in the prevention and / or treatment of depression, such as major depression in adults.
[0055] The present invention further provides a method for preventing and / or treating depression, e.g., major depression in an adult, comprising administering said vilazodone pharmaceutical composition, medicament and / or vilazodone pharmaceutical formulation to a patient, e.g., a human, in need thereof.
[0056] The present invention relates to a method for treating 5-hydroxytryptamine 1A (5-HT 1A) deficiency, comprising administering said vilazodone pharmaceutical composition, medicament and / or vilazodone pharmaceutical formulation to a patient, e.g., a human, in need thereof. 1A The present invention provides a method for partially agonizing 5-hydroxytryptamine (5-HT) reuptake and / or selectively inhibiting 5-hydroxytryptamine (5-HT) reuptake.
[0057] Since the active ingredient in the pharmaceutical composition of the present invention is vilazodone, a pharma- ceutically acceptable salt thereof or a solvate thereof known in the prior art, it should be understood that said pharmaceutical composition can be applied to diseases or conditions for which vilazodone, a pharma- ceutically acceptable salt thereof or a solvate thereof known in the prior art is applicable.
[0058] According to an embodiment of the present invention, unless otherwise specified, the "Dv(10)", "Dv(25)", "Dv(50)", "Dv(75)" and "Dv(90)" are volume-weighted particle diameters, of which 10 v / v%, 25 v / v%, 50 v / v%, 75 v / v% or 90 v / v% of particles have a diameter less than the respective volume weights when measured. For example, if the Dv(50) of a particle group is about 25 microns, it indicates that 50% of the volume of particles have a diameter of about 25 microns or less.
[0059] Unless otherwise specified, particle size parameters described herein, e.g., "D(10)," "D(25)," "D(50)," "D(75)," and "D(90)," are volume-weighted particle sizes and are equivalent to "Dv(10)," "Dv(25)," "Dv(50)," "Dv(75)," and "Dv(90)," respectively.
[0060] Without departing from the common knowledge in this field, each of the above preferred conditions can be combined in any way to obtain each preferred embodiment of the present invention.
[0061] All of the reagents and raw materials used in the present invention are commercially available.
[0062] According to an embodiment of the present invention, the room temperature is an environmental temperature of 10°C to 35°C.
[0063] The positive and advanced effects of the present invention are that the vilazodone pharmaceutical composition of the present invention overcomes the drawbacks of conventional vilazodone hydrochloride tablets, such as frequent dosing, difficulty in swallowing, and the unpleasant odor of the drug affecting patient compliance, and has obvious advantages such as long-term sustained release, reduced dosing frequency, and improved patient compliance, and has good prospects for marketing. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a particle size distribution diagram of vilazodone solid particles in the suspension in Example 1.
[0064] FIG. 2 is a polarized light microscope particle size morphology diagram of vilazodone solid particles in suspension in Example 1, with a scale of 15 microns.
[0065] FIG. 3 is a particle size distribution diagram of vilazodone solid particles in the suspension in Example 2.
[0066] FIG. 4 is a particle size distribution diagram of vilazodone solid particles in a suspension of Formulation 3 in Example 3.
[0067] FIG. 5 is a particle size distribution diagram of vilazodone solid particles in a suspension of Formulation 4 in Example 3.
[0068] FIG. 6 is a particle size distribution diagram of vilazodone solid particles in a suspension of Formulation 5 in Example 3.
[0069] FIG. 7 is a particle size distribution diagram of vilazodone solid particles in a suspension of Formulation 6 in Example 3.
[0070] FIG. 8 is an electron microscope photograph of vilazodone solid particles in a suspension of Formulation 6 in Example 3.
[0071] FIG. 9 is a graph showing the pharmacokinetic curve of vilazodone administered into the animals of group G1 in Example 4.
[0072] FIG. 10 is a graph showing the pharmacokinetic curve of vilazodone administered into the animals of group G2 in Example 4.
[0073] FIG. 11 is a graph showing the pharmacokinetic curve of vilazodone administered into the animals of group G3 in Example 4.
[0074] FIG. 12 is a graph showing the pharmacokinetic curve of vilazodone administered into the animals of group G4 in Example 4.
[0075] FIG. 13 is a graph showing the pharmacokinetic curve of vilazodone administered into the animals of group G5 in Example 4.
[0076] FIG. 14 is a graph showing the average pharmacokinetic curves of vilazodone administered into the animal bodies of groups G1 to G5 in Example 4. [Mode for carrying out the invention] The technical solution of the present invention will be described in more detail below with reference to specific examples. It should be understood that the following examples are merely illustrative and interpretive of the present invention and should not be interpreted as limiting the scope of the claims of the present invention. Any technology realized based on the above content of the present invention is included in the scope of the claims of the present invention.
[0077] Unless otherwise specified, all raw materials and reagents used in the following examples are commercially available or can be prepared by known methods. In the following examples, the experimental methods without specific conditions are selected according to conventional methods, conditions, or product specifications.
[0078] Unless otherwise specified, all mass volume ratios (W / V x 100%) described in this specification are in g / mL, and both disodium hydrogen phosphate and sodium dihydrogen phosphate used are anhydrous, and the ratios are calculated based on the molecular weights of the anhydrous forms.
[0079] Example 1
[0080] [Table 1]
[0081] The raw materials and auxiliary materials were weighed according to the amounts used in Recipe 1 in Table 1, and mixed uniformly to obtain a suspension. The particle size was measured using a laser particle size analyzer (the parameters of the laser particle size analyzer were: dispersion medium: water, refractive index of dispersion medium: 1.333, absorptivity of sample material: 0.05, refractive index of sample material: 1.711), and the particle size morphology of the particles in the suspension after grinding was observed under a polarizing microscope. The particle size distribution data of the vilazodone solid particles in the suspension are as shown in Table 2 and Figure 1. The polarizing microscope particle size morphology diagram of the vilazodone solid particles in the suspension is shown in Figure 2.
[0082] The particle shape and size observed under a polarizing microscope are consistent with the particle size measured by a laser particle size analyzer. The vilazodone solids in the suspension are agglomerates with sizes ranging from about 6 to 38 μm.
[0083] [Table 2]
[0084] Example 2
[0085] [Table 3]
[0086] The raw materials and auxiliary materials were weighed according to the amounts used in formula 2 in Table 3, and stirred and mixed to obtain an initial suspension. The initial suspension was added to 1.5 times the volume of 0.3 mm zirconium beads, placed in a polishing can for polishing, and polished for 10 hours to obtain a vilazodone pharmaceutical composition. The polishing was performed by a ball mill, and the parameters of the planetary ball mill were fixed parameters, with the diameter of the revolution disk being about 191 mm, the diameter of the rotation cup being about 71 mm, the height of the rotation cup being about 70 mm, the capacity of the rotation cup being 100 mL, the rotation speed of the revolution disk being 10 r / min, and the rotation speed being 720 r / min. The particle size was measured using a nanogranulometer (NICOMP Particle Sizing Systems, the parameters were: dispersion medium: water, dispersion medium refractive index: 1.333, viscosity: 0.933 cp, temperature: 23°C, light intensity setting value: 300 kHz).
[0087] The particle size distribution data of vilazodone solid particles in the suspension after grinding for 10 h with Formulation 2 are shown in Table 4 and FIG.
[0088] [Table 4]
[0089] Example 3
[0090] [Table 5]
[0091] The raw materials and auxiliary materials were weighed according to the prescribed amounts in Table 4, and stirred and mixed to obtain an initial suspension. The initial suspension was added to 1.5 times the volume of 0.6 mm zirconium beads, and placed in a polishing can for polishing. After polishing for 0 min, 5 min, 10 min and 10 h, the vilazodone pharmaceutical compositions of formulations 3, 4, 5 and 6 were obtained. The polishing was performed by a ball mill, and the parameters of the planetary ball mill were set as fixed parameters, with the diameter of the revolution disk being about 191 mm, the diameter of the rotation cup being about 71 mm, the height of the rotation cup being about 70 mm, the capacity of the rotation cup being 100 mL, the rotation speed of the revolution disk being 10 r / min and the rotation speed being 720 r / min.
[0092] The particle size and its distribution of formulations 3, 4 and 5 were measured by a laser particle size analyzer (the parameter settings of the laser particle size analyzer were: dispersion medium: water, dispersion medium refractive index: 1.333, sample material absorptivity: 0.05, sample material refractive index: 1.711). The particle size and its distribution of formulation 6 were measured using a nanogranulometer (NICOMP Particle Sizing Systems, the parameter settings were: dispersion medium: water, dispersion medium refractive index: 1.333, viscosity: 0.933cp, temperature: 23°C, light intensity setting: 300kHz).
[0093] The particle size distribution data of the vilazodone solid particles in the suspensions of Formulations 3, 4, and 5 are shown in Table 5 and Figures 4, 5, and 6. The particle size distribution data of the vilazodone solid particles in the suspension of Formulation 6 are shown in Table 6 and Figure 7.
[0094] The shape and size were observed by a scanning electron microscope (FEI, model F50). The scanning electron microscope voltage was 10 kV and the beam current was 2.0. The electron microscope photograph of the vilazodone solid particles in the suspension after polishing with the above formulation 6 is shown in Figure 8. Irregular agglomerated particles of 0.1 to 0.5 μm were observed.
[0095] [Table 6]
[0096] [Table 7]
[0097] Impact coefficient experiments were carried out for 0, 5 and 10 days under 4500LUX light irradiation and a high temperature of 60℃, and the related substances in the formulations were quantified by HPLC, with the results shown in Table 7. In formulations 3, 4, 5 and 6, the 0-day related substance RRT0.46 (oxidative decomposition impurities), RRT1.35 (acid-base decomposition impurities), maximum unknown single impurity and total impurity levels were all low, and under high temperature and light irradiation conditions, neither the known single impurity nor the maximum unknown single impurity increased, and only the total impurities increased slightly, indicating that the product has good stability.
[0098] [Table 8]
[0099] Example 4 Fifteen male rats were selected, and three rats in each group were randomly divided into five groups: control group (G1 group: formulation of 0.8% vilazodone and 0.25% cellulose HPMC aqueous solution), test group 1 (G2 group: Example 3, formulation 3), test group 2 (G3 group: Example 3, formulation 4), test group 3 (G4 group: Example 3, formulation 5), and test group 4 (G5 group: Example 3, formulation 6). The control group was intragastrically administered 4 mg / kg, and the test groups were intramuscularly injected with 120 mg / kg.
[0100] For animals in group G1, blood samples were taken before the first dose (D1) and at 0.5 h, 1 h, 2 h, 3 h, 5 h, 7 h, and 24 h after the dose, and for animals in groups G2 to G5, blood samples were taken before the first dose and at 1 h, 3 h, 7 h, 24 h, 96 h, 168 h, 264 h, 360 h, 480 h, 600 h, 720 h, 840 h, 960 h, and 1080 h after the dose. Before blood collection, the sampling tube containing EDTA-K2 was placed in an ice bath, the collected blood was added to the sampling tube, manually inverted at least five times, and stored in the ice bath; the blood was centrifuged at 2000 g for 10 min at 2 to 8 °C, and the centrifugation was completed within 2 hours after blood collection in both cases. The centrifuged plasma was transferred to a new labeled Ep tube and stored at -60 °C or lower. The concentration of vilazodone in rat plasma was analyzed by LC-MS / MS method, and the lower limit of quantification of this method was 0.500ng / mL. The concentration data was analyzed using the non-compartmental model method (NCA) of metabolic data analysis software WinNonlin 8.0.0.3176. The main pharmacokinetic parameters of vilazodone in the animal body are shown in Table 8, and the dosing time curves are shown in Figures 9-14. The results showed that the T1 / 2 and MRTlast of the test group were about 100-150 times and 50-70 times that of the control group, respectively, which indicated that the sustained release effect of the test formulation was significant; the Cmax of the test group was 40%-120% of the control group, which indicated that the test formulation had no risk of sudden drug release, the blood drug concentration was moderate, and poisoning and adverse reactions were unlikely to occur.
[0101] In this study, none of the animals in any group died or became moribund, and no obvious abnormal reactions were observed. The animals in groups G2 to G5 were euthanized after the last blood sample was taken, and the administration site was roughly observed, but no obvious abnormal pathological changes were observed, indicating that the test preparations had good safety.
[0102] [Table 9]
[0103] Example 5
[0104] [Table 10]
[0105] The raw materials and auxiliary materials were weighed according to the prescribed amounts in Table 9, and stirred and mixed to obtain an initial suspension. The initial suspension was added to 1.5 times the volume of 0.6 mm zirconium beads, and placed in a polishing can for polishing. After polishing for 10 hours, the vilazodone pharmaceutical composition of Formula 7 was obtained. The polishing was performed by a ball mill, and the parameters of the planetary ball mill were set as fixed parameters: the diameter of the revolution disk was about 191 mm, the diameter of the rotation cup was about 71 mm, the height of the rotation cup was about 70 mm, the capacity of the rotation cup was 100 mL, the rotation speed of the revolution disk was 10 r / min, and the rotation speed was 720 r / min.
[0106] The particle size and its distribution of Formulation 7 were measured by laser particle size analyzer (the parameter settings of the laser particle size analyzer were: dispersion medium: water, refractive index of dispersion medium: 1.333, absorptivity of sample material: 0.05, refractive index of sample material: 1.711). The particle size distribution data of vilazodone solid particles in the suspension of Formulation 7 is as shown in Table 10. Formulation 7 was subjected to accelerated stability test at 40°C and RH75%, and the test results of related substances are shown in Table 11. The related substances did not change significantly, indicating that the stability of the formulation is good.
[0107] [Table 11]
[0108] [Table 12]
[0109] Example 6
[0110] [Table 13]
[0111] Raw materials and auxiliary materials with different particle sizes were weighed according to the prescription usage amounts in Table 12, and the suspensions were prepared by stirring and mixing to obtain prescriptions 8 to 13. The particle size and its distribution were measured by a laser particle size analyzer (the parameter settings of the laser particle size analyzer were: dispersion medium: water, refractive index of dispersion medium: 1.333, absorptivity of sample material: 0.05, refractive index of sample material: 1.711). The needle permeability of the suspension was tested by aspirating with a 22g (outer diameter 0.7mm) needle, and the sedimentation volume ratio (H / H0) of the suspension was tested according to method 0123 of the General Provisions of the Chinese Pharmacopoeia 2020 Edition. The particle size distribution data, needle permeability, and sedimentation volume ratio of vilazodone solid particles in the suspensions of the above prescriptions 8 to 13 are shown in Table 13, and the results show that prescriptions 11, 12, and 13 have good needle permeability and a sedimentation volume ratio greater than 0.8, showing good injectability and suspendability.
[0112] [Table 14]
[0113] Example 7
[0114] [Table 15]
[0115] The raw materials and auxiliary materials with particle sizes (D10 = 8.4 μm, D50 = 20.6 μm, D90 = 43.9 μm) were weighed according to the prescription usage amounts in Table 14, and the suspensions were prepared by stirring and mixing to obtain prescriptions 14 to 23. The needle permeability of the suspensions was tested by aspirating with 22 g (outer diameter 0.7 mm) and 23 g (outer diameter 0.6 mm) needles, and the sedimentation volume ratio (H / H0) of the suspensions was tested according to Method 0123 of the General Provisions of the Chinese Pharmacopoeia 2020 Edition. The osmotic pressure, needle permeability, and sedimentation volume ratio of the suspensions of prescriptions 14 to 23 are shown in Table 15. According to the results, the pH of the above prescriptions 14 to 23 are all close to physiological pH, and the osmotic pressure meets the requirements of isotonicity. Regarding needle permeability, all formulations could be passed through a 22g needle, and especially formulation 22 could be passed through a 23g needle; formulations 18, 19, 20, and 21 had sedimentation volume ratios greater than 0.8 within the range of suspending agent concentration of 0-1%. The above data show that the physical properties, injectability, and suspendability of the formulations are good.
[0116] [Table 16] [Brief description of the drawings]
[0117] [Figure 1] FIG. 2 is a particle size distribution diagram of vilazodone solid particles in a suspension in Example 1. [Diagram 2] FIG. 2 is a polarized light microscope particle size morphology diagram of vilazodone solid particles in suspension in Example 1, with a scale of 15 microns. [Diagram 3] FIG. 2 is a particle size distribution diagram of vilazodone solid particles in a suspension in Example 2. [Figure 4] FIG. 1 is a particle size distribution diagram of vilazodone solid particles in a suspension of Formulation 3 in Example 3. [Diagram 5] FIG. 1 is a particle size distribution diagram of vilazodone solid particles in a suspension of Formulation 4 in Example 3. [Figure 6] FIG. 1 is a particle size distribution diagram of vilazodone solid particles in a suspension of Formulation 5 in Example 3. [Figure 7]FIG. 1 is a particle size distribution diagram of vilazodone solid particles in a suspension of Formulation 6 in Example 3. [Figure 8] 1 is an electron microscope photograph of vilazodone solid particles in a suspension of Formulation 6 in Example 3. [Figure 9] FIG. 1 shows the pharmacokinetic curve of vilazodone administered into the animals of group G1 in Example 4. [Figure 10] FIG. 1 shows the pharmacokinetic curve of vilazodone administered into the animals of group G2 in Example 4. [Figure 11] FIG. 1 shows the pharmacokinetic curve of vilazodone administered into the animals of group G3 in Example 4. [Figure 12] FIG. 1 shows the pharmacokinetic curve of vilazodone administered into the animals of group G4 in Example 4. [Figure 13] FIG. 1 shows the pharmacokinetic curve of vilazodone administered into the animals of group G5 in Example 4. [Figure 14] FIG. 13 is a graph showing the average pharmacokinetic curves of vilazodone administered into the animal bodies of groups G1 to G5 in Example 4.
Claims
1. A pharmaceutical composition comprising solid particles of vilazodone hydrochloride, the solid particles of vilazodone hydrochloride having a particle size of Dv(10) or less than 8 microns, a Dv(50) or less than 30 microns, and a Dv(90) or less than 80 microns.
2. The pharmaceutical composition of claim 1, wherein the solid particles of vilazodone hydrochloride have a particle size of Dv(10) of 0.1 to 8 microns; Dv(50) of 0.1 to 30 microns; and Dv(90) of 0.1 to 80 microns.
3. The pharmaceutical composition of claim 1, wherein the solid particles of vilazodone hydrochloride have a particle size of Dv(10) of 0.1 to 8 microns; Dv(50) of 5 to 26 microns; and Dv(90) of 5 to 80 microns.
4. The pharmaceutical composition further comprises a non-oil-based carrier or an oil-based carrier; the non-oily carrier is water; The oily carrier is one or more selected from castor oil, triglyceride, cottonseed oil, and sesame oil; and The pharmaceutical composition according to any one of claims 1 to 3, wherein the weight fraction of the solid particles of vilazodone hydrochloride is 1.00% to 50.00%, wherein the weight fraction is the percentage of the weight of the solid particles of vilazodone hydrochloride in the total weight of the pharmaceutical composition.
5. The pharmaceutical composition further comprises one or more selected from a suspending agent, a wetting agent, an osmotic pressure adjusting agent, a solvent, a stabilizer, a buffer, a pH adjusting agent, a surfactant, a polymer, an electrolyte, and a non-electrolyte; The suspending agent is one or more of sodium carboxymethylcellulose, polyethylene glycol, and povidone; the wetting agent is one or more of poloxamer, povidone, docusate sodium, sodium deoxycholate and Tween; the osmolality adjusting agent is one or more of sodium chloride, mannitol and sucrose; The solvent is water for injection; The stabilizer is one or more of antioxidants, metal ion chelators, polyethylene oxide, polyethylene oxide derivatives, polysorbates, sodium deoxycholate, sodium docusate, poloxamers, polyethoxylated vegetable oils, polyethoxylated castor oil, sorbitan palmitate, lecithin, polyvinyl alcohol, human serum albumin, polyvinylpyrrolidone, povidone, polyethylene glycol, sodium chloride, calcium chloride, dextrose, glycerol, mannitol, and cross-linked polymers; The buffering agent is selected from phosphoric acid, phosphates, citric acid, sodium citric acid, hydrochloric acid, sodium hydroxide, tris(hydroxymethyl)aminomethane, and mixtures thereof; and The pharmaceutical composition according to claim 4, characterized in that the pH adjusting agent is selected from phosphoric acid, phosphates, citric acid, sodium citric acid, hydrochloric acid and sodium hydroxide.
6. The antioxidant is one or more of citric acid, vitamin C, and vitamin E; the metal ion chelator is ethylenediaminetetraacetic acid; the poloxamer is one or more of poloxamer 188, poloxamer 124, and poloxamer 407; the polysorbate is one or more of polysorbate 80 and polysorbate 20; the povidone is one or more of povidone K12, povidone K17, PLASDONE™ C-12 povidone, PLASDONE™ C-17 povidone, and PLASDONE™ C-30 povidone; the polyethylene glycol is polyethylene glycol 3350; the cross-linked polymer is sodium carboxymethylcellulose; and 6. The pharmaceutical composition of claim 5, wherein the phosphate salt is one or more of disodium hydrogen phosphate monohydrate, disodium hydrogen phosphate dihydrate, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium dihydrogen phosphate dihydrate, and sodium dihydrogen phosphate anhydrous.
7. The pharmaceutical composition of claim 5 or 6, which may contain the following components in weight / volume (g / mL) percentages: 1.00% to 50.00% vilazodone solid particles, 0 to 5.00% humectant, 0 to 5.00% stabilizer, 0 to 5.00% osmotic pressure adjusting agent, 0 to 1.00% buffer salts and solvents; wherein the percentages are the mass / volume percentages (g / mL) of the weight of each component relative to the volume of the pharmaceutical composition.
8. The pharmaceutical composition according to claim 5 or 6, characterized in that the pharmaceutical composition comprises one formulation selected from the following: Formulation a: 30% vilazodone hydrochloride, 1% Tween 20, 2.15% mannitol, 0.08% anhydrous sodium dihydrogen phosphate, 0.4% anhydrous disodium hydrogen phosphate, the percentages being the weight percentages of each component in the total weight of the pharmaceutical composition; Formulation b: 5% vilazodone hydrochloride, 1% Tween 20, 0.3% PVPK12, 0.3% sodium deoxycholate, the percentages being the weight percentages of each component in the total weight of the pharmaceutical composition; Formulation c: 20% vilazodone hydrochloride, 1% Tween 20, 0.3% PVPk12, 0.3% sodium deoxycholate, 0.45% disodium hydrogen phosphate, 0.09% sodium dihydrogen phosphate, 2.5% mannitol, 0.18% sodium carboxymethylcellulose, the percentages being the weight percentages of each component relative to the total weight of the pharmaceutical composition; Formulation d: 36.3% vilazodone hydrochloride, 0.91% Tween 20, 0.34% disodium hydrogen phosphate, 0.07% sodium dihydrogen phosphate, 2.0% mannitol, 0.21% sodium carboxymethylcellulose, the percentages being the weight percentages of each component relative to the total weight of the pharmaceutical composition; Formulation e: 30% vilazodone hydrochloride, 1% Tween 20, 0.38% disodium hydrogen phosphate, 0.08% sodium dihydrogen phosphate, 2.20% mannitol, 0.23% sodium carboxymethylcellulose, the percentages being the weight percentages of each component in the total weight of the pharmaceutical composition; Formulation f: 30%-40% vilazodone hydrochloride, 1% Tween 20, 0%-0.3% PVP K12, 0.33%-0.39% disodium hydrogen phosphate, 0.07%-0.08% sodium dihydrogen phosphate, 1.6%-2.2% mannitol, 0%-1.0% sodium carboxymethylcellulose, the percentages being the weight percentages of each component in the total weight of the pharmaceutical composition; Formulation av: 30% vilazodone hydrochloride, 1% Tween 20, 2.15% mannitol, 0.08% sodium dihydrogen phosphate anhydrous, 0.4% disodium hydrogen phosphate anhydrous, the percentages being mass / volume percentages (g / mL) of the weight of each component relative to the volume of the pharmaceutical composition; Formulation bv: 5% vilazodone hydrochloride, 1% Tween 20, 0.3% PVPK12, 0.3% sodium deoxycholate, where the percentages are mass / volume percentages (g / mL) of the weight of each component relative to the volume of the pharmaceutical composition; Formulation cv: 20% vilazodone hydrochloride, 1% Tween 20, 0.3% PVPk12, 0.3% sodium deoxycholate, 0.45% disodium hydrogen phosphate, 0.09% sodium dihydrogen phosphate, 2.5% mannitol, 0.18% sodium carboxymethylcellulose, the percentages being the mass / volume percentages (g / mL) of the weight of each component relative to the volume of the pharmaceutical composition; Formulation dv: 36.3% vilazodone hydrochloride, 0.91% Tween 20, 0.34% disodium hydrogen phosphate, 0.07% sodium dihydrogen phosphate, 2.0% mannitol, 0.21% sodium carboxymethylcellulose, the percentages being mass / volume percentages (g / mL) of the weight of each component relative to the volume of the pharmaceutical composition; Formulation ev: 30% vilazodone hydrochloride, 1% Tween 20, 0.38% disodium hydrogen phosphate, 0.08% sodium dihydrogen phosphate, 2.20% mannitol, 0.23% sodium carboxymethylcellulose, the percentages being mass / volume percentages (g / mL) of the weight of each component relative to the volume of the pharmaceutical composition; and Formulation fv: 30%-40% vilazodone hydrochloride, 1% Tween 20, 0%-0.3% PVP K12, 0.33%-0.39% disodium hydrogen phosphate, 0.07%-0.08% sodium dihydrogen phosphate, 1.6%-2.2% mannitol, 0%-1.0% sodium carboxymethylcellulose, the percentages being mass / volume percentages (g / mL) of the weight of each component relative to the volume of the pharmaceutical composition.
9. A method for producing the pharmaceutical composition according to any one of claims 1 to 8, comprising the steps of: A manufacturing method comprising the steps of: Step 1: mixing solid particles of vilazodone hydrochloride with other ingredients in a formulation to obtain a premix; Step 2: milling the premix obtained in step 1 with zirconium beads to obtain the pharmaceutical composition.
10. Use of a vilazodone pharmaceutical composition according to any one of claims 1 to 8 in the manufacture of a medicament, comprising The medicament is one or more of a tablet, a granule, a capsule, a micropellet, an oral liquid, and an injection; The injection is a water suspension, a powder for injection, or a tablet for injection; The medicament is 5-hydroxytryptamine 1A (5-HT 1A ) acting as partial agonists and / or selective 5-hydroxytryptamine (5-HT) reuptake inhibitors (SSRIs), for use.
Citation Information
Patent Citations
Pharmaceutical compositions of vilazodone hydrochloride
EP3360543A1
Combination of serotonin reuptake inhibitors and histamine 3 receptor antagonists, inverse agonists or partial agonists
JP2007513896A
